briakinumab
Sign in to saveBriakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
~2 min read
Encyclopedic overview
4 sectionsContents
- Discovery
- Trials
- Royalties
- References
Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
Like ustekinumab, the antibody targets the interleukins 12 and 23.
Excerpted from Wikipedia’s “briakinumab” article, available under the CC BY-SA 4.0 licence.